| Autor: |
Garland RJ; Department of Pathology and Microbiology, University of Bristol, University Walk, Bristol, UK. R.Garland@bristol.ac.uk, Groves SJ, Diamanti P, West SE, Winship KL, Virgo PF, Robinson SP, Oakhill A, Cornish JM, Pamphilon DH, Marks DI, Goulden NJ, Steward CG |
| Jazyk: |
angličtina |
| Zdroj: |
Bone marrow transplantation [Bone Marrow Transplant] 2005 Aug; Vol. 36 (3), pp. 237-44. |
| DOI: |
10.1038/sj.bmt.1705049 |
| Abstrakt: |
CAMPATH-1H (C-1H) is widely used in vivo and / or in vitro for T cell depletion in hematopoietic SCT. This humanised monoclonal antibody is specific for CD52, a marker coexpressed on the majority of human lymphocytes with CD48 and other glycosylphosphatidyl-inositol (GPI) anchored proteins. We detected CD52 / CD48 dual expression on >99% of CD3(+) lymphocytes from normal individuals and all 15 post-SCT patients whose transplants did not utilise C-1H. By contrast, 23 / 26 patients with transplants involving C-1H (in vivo, in vitro or both) exhibited populations lacking CD52 expression that accounted for 49.7% (4.2-86.2%) of the CD3+ lymphocytes (median and range) in samples evaluated at a median of 2 months post-SCT. Most CD52- cells also lacked CD48 expression. These GPI- T cells were of either donor or mixed donor / recipient origin. They were predominant in the early months after SCT at times of profound lymphopenia and inversely correlated with the recovery of the absolute lymphocyte count (r= - 0.663, P<0.0001). The presence of CD52- cells has been correlated previously with clinical outcome after CAMPATH therapy for both malignant and nonmalignant diseases. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
